Allergan and Adamas enter settlement with Amneal Pharmaceuticals
Thursday, September 01, 2016
Allergan and Adamas announce settlement with Amneal related to namzaric patent litigation. Adamas will grant amneal a license to market generic versions of namzaric beginning on January 1, 2025.
Other terms of settlement were not disclosed.
Under certain circumstances, amneal has an option to launch an authorized generic version of namzaric beginning on January 1, 2026.
Settlement provides additional clarity for patent-protected life of namzaric.
Alternatively, under certain circumstances, amneal has option to launch authorized generic version of namzaric beginning on January 1, 2026.
Source : reuters.com
